One pundit believes this is a clinical-stage company well worth watching.Highly specialized biotech CG Oncology (CGON 7.13%) was the subject of a new research report Wednesday, and its bullish tone helped lift the company's share price. This improved by more than 7% on the day, easily beating the 0.6% advance of the bellwether S&P 500 (^GSPC 0.58%). A biotech with a tight focusThat publication marked the initiation of coverage on CG Oncology stock by veteran researcher Guggenheim, in the person of prognosti ...

IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder- sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates. "In 2025, we made further progress advancing cretostimogene monotherapy as a bladder-sparing backbone therapy for patients with NMIBC," said Arthur ...